HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

JW Therapeutics - Concerns Are in the Short Term but Still Promising in the Long Term

Jiangsu Hengrui Medicine (600276 CH) - Q3 Performance Improved with Promising Innovative Pipeline

RemeGen (荣昌生物) Pre-IPO: Thoughts on Valuation of RC18 and RC48

A Different Angle - Simcere Pharmaceutical VS Everest Medicines (01952.HK)

Pre-IPO JD Health (JDH.HK) - A Better Candidate of Online Healthcare Business In China?

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

<p style="text-align: justify;"><a href="https://www.smartkarma.com/entities/remegen-ltd" target="_blank" data-smartkarma-citation="entities:29191:1" rel="noopener">Remegen Ltd (1788976D CH)</a> has developed a comprehensive pipeline of more than 10 new biological drug candidates for the treatment of refractory diseases, including autoimmune diseases, tumors and eye diseases, that meet a large number of unmet medical needs in China and around the world. Among these drug candidates, two core products are RC18 and RC48. Both are at late clinical stage and would probably be the first two drugs to be commercialized for RemeGen.</p>

Remegen Ltd (1788976D CH) has developed a comprehensive pipeline of more than 10 new biological drug candidates for the treatment of refractory diseases, including autoimmune diseases, tumors and eye diseases, that meet a large number of unmet medical needs in China and around the world. Among these drug candidates, two core products are RC18 and RC48. Both are at late clinical stage and would probably be the first two drugs to be commercialized for RemeGen.

Pre-IPO RemeGen - Insights on Two Core Products RC18 & RC48